5-7 December 2017

London, UK

Save £700 – Register Now

Day One
Wednesday, 6th December 2017

Day Two
Thursday, 7th December 2017

Registration and Networking

Chair’s Opening Remarks

Optimising Preclinical Data Packages to Improve Translational Research

Identifying Responsive Patient Populations in the Preclinic: Adopting Clinically-Relevant Models Across Oncology Therapeutics

  • Rajendra Kumari General Manager & Chief Scientific Officer, Crown Bioscience UK Ltd


  • Developing CDX and PDX modelling for breast and prostate cancer to enhance translational success
  • How to satisfy the demand for clinically relevant models for understanding disease progression
  • Models you need, when you need them and how to interpret the data effectively to reduce cost

How to Achieve Predictability in Development and Monitoring of Tumour Microenvironment Directed Therapies?


  • Ex vivo tissue culture of human tumour specimen: human bladder cancer points the way
  • From clinic to bench side: challenges in clinical tumour sample investigations
  • Walking the immune microenvironment landscape: lessons from expression to multi-marker cell profiling
  • One is not enough: Multivalent immune gene therapy for multi-target tumour microenvironment reprogramming by Immunalon®

The Application of Network Driven Drug Discovery to Identify Novel First in Class Small Molecules Across a Variety of Oncology Indications


  • Combining a unique computer-based platform with biological expertise to create and analyse in silico network models of disease
  • Network Driven Drug Discovery providing rational choices for further testing in in vitro phenotypic screening
  • Applying in vivo preclinical models to identify novel lead molecules in oncology drug discovery

Utilising Multicellular 3D Models for Preclinical Drug Discovery


  • Primary 3D cell cultures from patient material
  • Addition of monocytes or fibroblasts to identify a potential trophic role
  • Influence of microenvironment on stemness
  • Transplantation of multicellular spheres to create tumours with microenvironment

Speed Networking

Morning Refreshments

Minimising the Translational Gap from Preclinical to Clinical through Next Generation In Vivo Models

Incorporating CRISPR into the pre-clinical testing of TCR-based biologic drug candidates


  • Analysing the need of predicting off-target effects in the preclinical testing of tumour immunotherapy candidates
  • Overview on validated preclinical tests to assess potency and cross-reactivity
  • Applying CRISPR to preclinical: benefits and challenges.

INOVOTION Technology for Oncology Drug Discovery: Early In Vivo Identification of Low Value Molecules


• How to use INOVOTION technology to open new perspectives of in vivo screening for
anti-caner treatments
• Why chick embryo model has several advantages for drug discovery in oncology
• Chick embryo model fills the gap between in vitro and mouse model but is it possible to
predict mouse data from chick embryo results

Remodelling Barrett’s Metaplasia in a Novel In Vivo Organoid Model


  • Successful intramuscular engraftment of Barrett’s oesophagus biopsies
  • In vivo organoid structures were of human origin and expressed the appropriate markers of intestinal differentiation
  • BMP inhibition prevented proliferation of columnar cells and therefore may be used to treat Barrett’s oesophagus and prevent the development of oesophageal adenocarcinoma

Networking and Lunch

Utilising More Clinically Relevant Humanised Mouse Models

Role of Genetically Engineered Mouse Models in Drug Discovery


  • Key challenges using classic syngeneic models for drug discovery
  • Potential for using genetically engineered mouse models to support understanding of dose and schedule
  • Looking to the future: How can GEMMs be used?

Utilising Sophisticated Mouse Models to Better Understand the Pathways and Mechanisms of Emerging Immune Therapies

  • James Keck Senior Director In Vivo Pharmacology, Jackson


  • Understand how animal models can provide accurate in vivo conditions to mimic the natural tumour environment
  • Hear the latest case studies in the use and relevance of humanised mice
  • Explore how to successfully use humanised models to select combinations of immunotherapies

Developing an in vivo model for Proof of Concept of small molecules targeting the myeloid compartment


  • Targeting S100 A9 to counteract cancer progression
  • Pros and Cons of syngeneic vs humanised models
  • Advancing the PoC in a humanised model

How To Advance PDX Tumour Biology Platforms for Drug Advancement

  • Neal Goodwin Vice President Corporate Research, Champions Oncology


  • Large collections of PDX models allow for more resolute efficacy predictions and the discovery of new therapeutic targets
  • Why creating robust systems of myeloid engraftment allow for expanded PDX screening with a wider scope of therapeutics agents
  • Combining clinical trials with companion PDX studies to guide follow-on trial design

Afternoon Refreshments

Humanised Mouse Models for Immunotherapy Pipeline Advancement


  • Overview of different classes of humanised mouse models
  • Advantages and pitfalls of humanised mouse models
  • In vivo profiling of cancer immunotherapies in humanised mouse models

PDX Models Recapitulate Clinical Tumour Progression


  • PDXs models of patient’s sequential biopsies mimic disease progression: case studies
  • Incorporating human-microenvironment component into PDX models
  • Novel humanised mice model for I/O studies: same-patient immune system and tumour tissue in one mouse

The Repositive PDX Resource – A Collaborative Resource Providing Improved Access to Find and Select PDX Models From World-wide PDX Vendors


  • Overview of Repositive and its mission to help researchers help patients faster
  • Introduction to the Repositive PDX Platform, its features and the benefits to simplify workflows for PDX researchers and PDX vendors
  • A vision for the future: partnerships and collaboration

Chairperson’s Closing Remarks

Drinks Reception hosted by Crown Bioscience